The Claims

1 – 10. (Cancelled)

11. (Previously Presented) The compound of claim 34 represented by the formula:



wherein

R_{11} is selected from the group consisting of C_5-C_{12} alkyl, C_5-C_{12} alkoxy, C_5-C_{12} alkenyl, and C_5-C_{12} alkynyl;

R_7 and R_8 are independently selected from the group consisting of O, S, NR_{26}, and N;

wherein R_{26} is H, F or C_1-C_4 alkyl;

R_{25} is CH;

R_2 is NH_2;

R_3 is selected from the group consisting of H, C_1-C_4 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



;

wherein X and R_{12} are independently selected from the group consisting of O and S;

R_{23} is selected from the group consisting of H, F, OH, C_1-C_4 alkyl, CO_2H and C_1-C_4 alkyl;

R_{24} is selected from the group consisting of H, F, C_1-C_4 alkyl and PO_3H_2, or R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group; and

y and m are integers independently ranging from 0 to 4;

or a pharmaceutically acceptable salt or tautomer thereof.

12. (Original) The compound of claim 11 wherein

m is 0;

y is 0 or 1;

R_{25} is CH;

R_{23} is H or F; and

R_{24} is selected from the group consisting of H, F and C_1-C_4 alkyl.

13. (Original) The compound of claim 11 wherein R_3 is selected from the group consisting of C_1-C_3 alkyl and (C_1-C_4 alkyl)OH.

14. (Original) The compound of claim 12 or 13 wherein

R_7 is NH; and

X is O;

or a pharmaceutically acceptable salt or tautomer thereof.

15. (Original) The compound of claim 14 wherein

y is 0; and

R_{15} is OH.

16. (Previously Presented) The compound of claim 13 represented by the formula:



or



wherein R_{11} is C_5-C_{18} alkyl, C_5-C_{12} alkoxy, or C_5-C_{18} alkenyl; and

R_8 is N;

or a pharmaceutically acceptable salt or tautomer thereof.

17. (Original) The compound of claim 16 wherein R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S;

or a pharmaceutically acceptable salt or tautomer thereof.

18. (Original) The compound of claim 17 wherein R_{11} is C_5-C_9 alkyl;

R_{15} is OH and

R_3 is selected from the group consisting of CH_3, CH_2CH_3, CH_2OH, CH_2CH_2OH and $CH_2CH_2CH_2OH$.

19. (Previously Presented) A composition comprising a compound of claim 34, 11 or 16 and a pharmaceutically acceptable carrier.

20. (Previously Presented) A pharmaceutical composition comprising a compound represented by the formula:



wherein R_{11} is C_5-C_{18} alkyl C_5-C_{12} alkoxy or C_5-C_{18} alkenyl;

Q is imidazolyl;

R_3 is selected from the group consisting of H, C_1-C_4 alkyl and (C_1-C_4 alkyl)OH;

R_{23} is H or C_1-C_4 alkyl, and

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein X and R_{12} are independently selected from the group consisting of O and S;

or a pharmaceutically acceptable salt or tautomer thereof and

a pharmaceutically acceptable carrier.

21. (Cancelled)

22. (Previously Presented) The composition of claim 38 wherein R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S.

23 - 27. (Cancelled)

28. (Previously Presented) A method of promoting wound healing in a warm blooded vertebrate, said method comprising the step of administering a composition comprising a compound of the general structure:



wherein R_{11} is C_5-C_{18} alkyl, C_5-C_{12} alkoxy, or C_5-C_{18} alkenyl;

Q is imidazolyl;

R_3 is selected from the group consisting of H, C_1-C_4 alkyl and (C_1-C_4 alkyl)OH;

R_{23} is H or C_1-C_4 alkyl, and

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein X and R_{12} are independently selected from the group consisting of O and S;

or a pharmaceutically acceptable salt or tautomer thereof.

29 - 33. (Cancelled)

34. (Previously Presented) A compound represented by the formula:



wherein

R_{11} is selected from the group consisting of C_5-C_{12} alkyl, C_5-C_{12} alkenyl, C_5-C_{12} alkynyl, C_5-C_{12} alkoxy, $(CH_2)_pO(CH_2)_q$, C_5-C_{10} (aryl)R_{20}, C_5-C_{10} (heteroaryl)R_{20}, C_5-C_{10} (cycloalkyl)R_{20}, C_5-C_{10} alkoxy(aryl)R_{20}, C_5-C_{10} alkoxy(heteroaryl)R_{20} and C_5-C_{10} alkoxy(cycloalkyl)R_{20};

wherein R_{20} is H or C_1-C_{10} alkyl;

R_{29} is H or halo;

R_2 is NH_2;

R_3 is selected from the group consisting of H, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{23} is selected from the group consisting of H, F, NH_2, OH, CO_2H, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{24} is selected from the group consisting of H, F and PO_3H_2, or R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group;

R_7, and R_8 are independently selected from the group consisting of O, S, NR_{26}, and N;

R_{25}, is CHR_{26};

wherein R_{26} is H, F or C_1-C_4 alkyl;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein R_{12} is selected from the group consisting of O, NH and S;

X is selected from the group consisting of O, NH and S;

y and m are integers independently ranging from 0 to 4;

p and q are integers independently ranging from 1 to 10;

or a pharmaceutically acceptable salt or tautomer thereof.

35 – 43 (Cancelled)

44. (Previously Presented) The method of claim 28 wherein R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S.

45. (Previously Presented) The method of claim 44 wherein R_{15} is OH or a pharmaceutically acceptable salt or tautomer thereof.